ACT Biotech - Molecule Drug Asset's Unit Acquisition

ACT Biotech - Molecule Drug Asset raised a round of funding on February 19, 2014. Investors include Eddingpharm.

ACT Biotech aims to bring therapies to bear in managing cancer, especially in underserved disease sectors where patient need is acute. Per the company, ACT has launched an aggressive, focused developm…

Articles about ACT Biotech - Molecule Drug Asset's Unit Acquisition: